To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Dalton Medicinal Chemistry Partners Signs Agreement with Boehringer Ingelheim
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces the signing of a Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners will utilise their medicinal chemistry expertise to design and synthesise novel compounds against a number of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd.
Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to enter this exciting partnership with Boehringer Ingelheim (Canada) Ltd by bringing the added value of our medicinal chemistry capabilities and expertise to their antiviral research projects."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
